Drug
Ipragliflozin clinical trials
Also written ASP1941.
- studies test it
- 48
- open now
- 0
- in phase 3
- 16
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Development codes
- ASP1941
- 44
Studies by the year they started
48 studies that test it; most in 2010 (15)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 15 |
| 2011 | 8 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 5
- Phase 3
- 16
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 46 · Other 2
Astellas Pharma Inc (38) · Astellas Pharma Europe B.V. (3) · Astellas Pharma Korea, Inc. (2) · Merck Sharp & Dohme LLC (2) · Seoul National University Bundang Hospital (1) · Yonsei University (1) · Astellas Pharma Global Development, Inc. (1)
Often tested with
Tested in the same studies.
Sitagliptin (2) · Glimepiride (2) · Nateglinide (1) · Dipeptidyl-Peptidase IV Inhibitors (1) · Insulin (1) · Furosemide (1) · Mitiglinide (1) · Miglitol (1)
Studies
Open first, then newest update. How each study uses ipragliflozin is read from its arms, and is right about nine times in ten.
Testing it · 48
- A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01054092Written as ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01225081Written as ipragliflozin
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01242202Written as ipragliflozin
- A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01316107Written as ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes PatientsCompletedPhase 3Astellas Pharma IncNCT01057628Written as ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01135433Written as ipragliflozin
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01242228Written as ipragliflozin
- A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal ImpairmentCompletedPhase 3Astellas Pharma IncNCT01316094Written as ASP1941
- A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT01071850Written as ipragliflozin
- A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT01117584Written as ipragliflozin
- A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.CompletedPhase 2Astellas Pharma IncNCT00790660Written as ASP1941
- Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin TherapyCompletedPhase 4Astellas Pharma IncNCT02847091Written as Ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes PatientsCompletedPhase 3Astellas Pharma IncNCT01505426Written as ASP1941
- A Study of ASP1941 in Participants With Type 2 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT00621868Written as ipragliflozin
- A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal ImpairmentCompletedPhase 1Astellas Pharma IncNCT01097681Written as ASP1941
- A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes MellitusCompletedPhase 3Astellas Pharma IncNCT02897219Written as ipragliflozin
- Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT02529449Written as ASP1941
- A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinCompletedPhase 3Astellas Pharma Korea, Inc.NCT02452632Written as ASP1941
- A Study of ASP1941 in Japanese Patients With Type 2 Diabetes MellitusCompletedPhase 1Astellas Pharma IncNCT01023945Written as ASP1941
- A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusTerminatedPhase 3Astellas Pharma IncNCT01514838Written as ASP1941
See all 48 studies that test ipragliflozin →
Given in every arm · 1 — ipragliflozin is usual care beside what is tested
Codes
What other systems call ipragliflozin · ClinicalTrials.gg INT006079
- MeSH (NLM) C572941ipragliflozinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3N2N8OOR7XIPRAGLIFLOZINConfirmed FDA, NLM, Wikidata
- Wikidata Q17193526ipragliflozinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166685IpragliflozinOne source FDA
- DrugBank DB11698One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572941 | ipragliflozin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3N2N8OOR7X | IPRAGLIFLOZIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q17193526 | ipragliflozin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166685 | Ipragliflozin | One source FDA |
| DrugBank | DB11698 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.